To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis
This trial is active, not recruiting.
|Treatments||pyrimethamine-sulfadiazine + prednisolone, clindamycin+dexamethasone|
|Sponsor||Shahid Beheshti Medical University|
|Start date||July 2005|
|End date||August 2008|
|Trial identifier||NCT00372294, 8415|
Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||single blind (subject)|
Male or female participants of any age.
Inclusion Criteria: - Patients with Toxoplasmic chorioretinitis - Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III - No allergic history to the used drugs - No any other diseases Exclusion Criteria: - Any allergic reaction to the used medications - One eyed patients - Partially treated patients
|Principal investigator||Masoud Soheilian, MD|
Call for more information